|
||||||||
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
SELECT PUBLICATIONS
Baum M, Ravdin P. Decision-making in early breast cancer: Guidelines and decision tools. Eur J Cancer 2002;38(6):745-9. Abstract
Berry DA et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006;295:1658-67. Abstract
Goldhirsch A et al. Meeting highlights: International expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005;16(10):1569-83. Abstract
Henderson IC et al. Improved disease-free and overall survival from the addition of sequential paclitaxel but not from the escalation of doxorubicin dose level in the adjuvant chemotherapy of patients with node-positive primary breast cancer. Proc ASCO 1998;Abstract 390.
Martin M et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005;352(22):2302-13. Abstract
Olivotto IA et al. Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 2005;23(12):2716-25. Abstract
Peele PB et al. Decreased use of adjuvant breast cancer therapy in a randomized controlled trial of a decision aid with individualized risk information. Med Decis Making 2005;25(3):301-7. Abstract
Piccart-Gebhart MJ. Treatment guidelines for systemic adjuvant therapy of breast cancer: Strengths and weaknesses. San Antonio Breast Cancer Symposium 2005;Abstract P1.
Ravdin PM et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001;19(4):980-91. Abstract
 |
 |
